secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001558370-22-017572
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios reports Q3 net loss $2.6M, cash $9.8M, advances IMC-1 to Phase 3 based on post-hoc FORTRESS analysis
--------------------------------------------------------------------------------

- Net loss of $2.6M ($0.28 per share) for Q3 2022 vs $4.1M ($0.49) in Q3 2021.
- Cash totaled $9.8M as of Sep 30, 2022; company expects to fund operations through end of 2023.
- Post-hoc FORTRESS analysis shows significant pain reduction in fibromyalgia patients naive to prior trials/treatment.
- Company plans to meet with FDA to discuss advancing IMC-1 into Phase 3 development.
- Raised $5M in September 2022 equity capital to support IMC-1 development and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837022017572/0001558370-22-017572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837022017572/tmb-20221114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer